Oncology
Initial Safety and Efficacy Data for NKTR-255, a Novel IL-15 Agonist, in Combination with Cetuximab in Solid Tumors Presented in Late-Breaking Abstract Session SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. Excerpt from the Press Release: Initial clinical…
Read More
21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Conference Call and Webcast on Saturday, November 13 at 5:30pm ET Excerpt from the Press Release: SAN CARLOS, Calif., and WASHINGTON, Nov. 12, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel…
Read More
Excerpt from the Press Release: Data showed Amphiphile (AMP) boosting significantly enhanced TCR-T cell anti-tumor efficacy and led to durable responses against solid tumors in an established, syngeneic tumor model AMP boosting of CD19-specific CAR-T cells led to enhanced CAR-T activation and effector function suggesting the platform can potentially be utilized to improve clinical CD19…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual…
Read More
Excerpt from the Press Release: Monotherapy data further enhances confidence in CUE-101 potential as single agent therapeutic in the refractory/metastatic human papillomavirus positive head and neck squamous cell carcinoma (HPV+ HNSCC) setting Early CUE-101 combination data with KEYTRUDA® (pembrolizumab) supports potential mechanistic activity CUE-102 in vivo data demonstrated ability to selectively activate and expand Wilms’…
Read More
Bluestar Genomics Presents New Data Showing its Liquid Biopsy Test Detects Pancreatic Cancer Signal.
-Analytical performance data presented at the American Pancreatic Association meeting- -The company also appointed seasoned industry leader Jim Vaughn as its chief commercial officer- Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Bluestar Genomics, an innovative company leading the development of next-generation liquid biopsy approaches to early cancer detection, today announced the presentation of new analytical…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, Nov. 4, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the first patient has been dosed in its global ACE-Breast-03 Phase 2 clinical study of ARX788 in patients with HER2-positive metastatic breast…
Read More
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the first patient has been dosed in KZR-261-101, a Phase 1 clinical trial evaluating KZR-261, a novel, broad-spectrum, anti-tumor agent that acts through direct…
Read More
Excerpt from the Press Release: PLEASANTON, Calif., Oct. 27, 2021 /PRNewswire/ — DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the publication of a study in PLOS ONE that demonstrates that DiaCarta’s ColoScape™ Xenonucleic Acid (XNA)-mediated quantitative real-time polymerase chain reactions (qPCR) clamping assay detects mutant cell-free DNA (cfDNA)…
Read More